The UK’s medicines and medical devices regulator has recruited one of America’s most accomplished public health technology executives to lead a fundamental overhaul of its digital infrastructure.

A Bold Hire For A Regulator Under Pressure To Modernise

Recruiting a senior technology leader from one of the world’s most prominent public health institutions is not a routine appointment. Jason Bonander officially began his role as the MHRA’s Chief Digital and Technology Officer on 27 May 2026, stepping into a newly elevated position at an agency that regulates every medicine and medical device available to patients across the UK.

The timing is deliberate. The MHRA is preparing to publish a new five-year strategic plan covering through to 2030, and Bonander’s arrival is designed to anchor that strategy in credible, experienced digital leadership rather than aspiration alone.

Two Decades Shaping Digital Health At The CDC

Bonander joined the CDC in 2001 and over two decades built one of the most varied portfolios of any health informatics leader in the US federal government, eventually serving as Chief Information Officer. He oversaw global cybersecurity, enterprise cloud strategy, and data-sharing infrastructure across federal, state, and local public health bodies. His tenure spanned the COVID-19 pandemic, during which he led rapid adaptation of the agency’s digital capabilities under extraordinary operational pressure.

That combination of scale, cybersecurity expertise, and health data strategy is directly relevant to what the MHRA now needs. MHRA Chair Professor Anthony Harnden said: “Jason brings exceptional experience in digital transformation and health technology. His leadership will be critical as we modernise our systems and services to support faster, more efficient regulation for the benefit of patients across the UK.”

The Digital Reset The MHRA Needs

The MHRA’s digital infrastructure has faced well-documented difficulties. A significant investment in a new regulatory submissions portal, launched in 2024, was withdrawn in late 2025 after failing to deliver the intended efficiencies, leaving the agency to develop a replacement under its forthcoming strategy. Meanwhile, it has been pushing forward on AI integration within its own assessment workflows and running its AI Airlock programme, through which emerging technologies including AI-assisted clinical note-taking and diagnostics are guided through regulatory evaluation in a structured way.

Chief Executive Lawrence Tallon said: “Jason’s expertise in digital transformation and health informatics is exactly what the MHRA needs as we modernise how we regulate medicines and medical devices.”

What This Means For Care Technology Providers

For organisations operating in the UK home care and community health technology sector, the quality of MHRA regulation directly affects how quickly useful innovations can be approved and deployed. Remote patient monitoring devices, connected medication dispensers, AI-driven fall-detection systems, and digital care coordination platforms all fall within the MHRA’s regulatory scope. The clearer and more predictable the regulatory pathway, the more readily care providers and commissioners can invest in evidence-based technologies.

The UK digital health market is estimated at around £15 billion for 2025 and 2026. Regulatory drag has a genuine economic cost and it also delays access for patients who stand to benefit. The strengthening of cooperation between the MHRA and the US Food and Drug Administration, announced in April 2026, adds further promise, offering reduced duplication for companies seeking approval in both markets.

Building Trust Alongside Pace

Bonander has signalled a consultative opening to his tenure. “My goal in the early months is to listen and learn from colleagues across MHRA and from partners throughout the wider health and regulatory ecosystem,” he said. His broader framing is equally instructive: “Digital, data and technology are inseparable from how people experience health, healthcare and regulation, and our shared responsibility is to ensure we use them safely, responsibly and at pace in ways that protect health, support innovation and strengthen public trust.”

That emphasis on trust alongside pace reflects a clear-eyed understanding of why regulatory technology differs from commercial digital transformation; the consequences of failure are measured in patient safety, not just operational setbacks. With a new five-year strategy on the horizon and an experienced CDTO now in post, the MHRA enters its next chapter better positioned than it has been in years. Whether that translates into faster, smarter regulation for the UK care sector will become clear soon enough.